GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

Main Article Content

Vincenzo De Sanctis
Ashraf Soliman
Shahina Daar
Ploutarchos Tzoulis
Salvatore Di Maio
Christos Kattamis

Keywords

β-thalassemia major; Iron overload; Oral glucose tolerance test; Glucose tolerance abnormalities; Insulin sensitivity; Insulin resistance

Abstract

Aims: The primary aim of this study was to evaluate retrospectively the glucose homeostasis and surrogate indexes of insulin sensitivity and resistance, during a 3-hour oral glucose tolerance test (OGTT), in β- thalassemia major patients (β-TM) with serum ferritin (SF) below 1,000 ng/mL.


Patients and methods: The retrospective cohort study evaluated the medical records of 24 β-ΤΜ patients from 2010 to 2022. Αt the year of study the mean age of patients was 31.0 ± 4.1 (20-37.11) years; 13 (54.1%) were females. The most commonly used iron chelator was deferoxamine (DFO: 75%), followed by deferiprone (DFP:12.5%) and deferasirox (DFX: 12.5%). Insulin sensitivity and resistance indexes were derived from OGTT. A liver iron concentration (LIC) < 3 mg/g d.w. and a global heart T2* value < 20 ms were considered as conservative cut-off values for insignificant iron overload (IOL).


Results: The mean SF levels in the whole study cohort population at the age of evaluation was 549.6 ± 232.3 ng/mL. Based on the SF levels, two groups were identified: Group A (N = 14) < 500 ng/mL and Group B (N=10) 500-1,000 ng/mL.  Normal glucose tolerance (NGT) during OGTT was observed in 4 patients of Group A (28.5 %) and in 5 patients of Group B (50%) (P: 0.29). The remaining 15/24 patients (62.5%) had glucose dysregulation (GD). The mean age at starting iron chelation therapy (ICT) and the mean SF peak in Group A versus Group B were significantly higher in group Α.  The GD was  associated with significantly attenuated IGI (first phase of insulin response) and impaired oral disposition index (oDI). Hypogonadotropic hypogonadism (HH) was the most common associated endocrine complication in both groups of patients.


Conclusions: This study showed that efficient iron chelation monotherapy in patients with β-TM and SF < 1,000 ng/ml did not entirely prevent glucose metabolism disorders, insulin secretion and sensitivity, and development of acquired hypogonadism.

Downloads

Download data is not yet available.
Abstract 301 | PDF Downloads 94 HTML Downloads 39

References

1. Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet. 2022;399(10343):2310-2324. doi: 10.1016/S0140-6736(22)00536-0.

2. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021;9(12):e1788. doi: 10.1002/mgg3.1788.

3. Carsote M, Vasiliu C, Trandafir AI, Albu SE, Dumitrascu MC, Popa A, Mehedintu C, Petca RC, Petca A, Sandru F. New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement. Diagnostics (Basel). 2022;12(8):1921. doi: 10.3390/diagnostics12081921.

4. Sevimli C, Yilmaz Y, Bayramoglu Z, Comert RG, Gul N, Dursun M, Karakas Z. Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience. Clin Exp Med. 2022;22(1):95-101. doi: 10.1007/s10238-021-00735-7.

5. Reddy PS, Locke M, Badawy SM. A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. Ann Med. 2022 ;54(1):326-342. doi: 10.1080/ 07853890. 2022. 2028894.

6. Wahidiyat PA, Yosia M, Sari TT. Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta Med Indones. 2018;50(2):168-176. PMID: 29950538.

7. Spasiano A, Meloni A, Costantini S, Quaia E, Cademartiri F, Cinque P, Pepe A, Ricchi P. Setting for "Normal" Serum Ferritin Levels in Patients with Transfusion-Dependent Thalassemia: Our Current Strategy. J Clin Med. 2021;10(24):5985. doi: 10.3390/jcm10245985.

8. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020; 43(Suppl.1): S14-S31.https://doi.org/10.2337/dc20-S002.

9. WHO Multicentre Growth Reference Study Group . WHO child growth standards: Length/height-for-age, weight-for-age, weight-for-length, weight-forheight and body mass index-for-age: Methods and development. WHO Child Growth Standards. [Internet]. 2006;52:13–17.

10. De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, Karimi M, Yassin MA, El Awwa A, Stoeva I, Raiola G, Galati MC, Bedair EM, Fiscina B, El Kholy M. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17(1):8-18. doi: 10.4103/2230-8210. 107808.

11. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452. PMID: 8594834..

12. Kasim N, Khare S, Sandouk Z, Chan C. Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100275. doi: 10.1016/j.jcte.2021.100275.

13. Tschritter O, Fritsche A, Shirkavand F, Machicao F, Häring H, Stumvoll M. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care. 2003;26(4):1026-1033. doi: 10.2337/diacare.26.4.1026.

14. Cai X, Han X, Zhou X, Zhou L, Zhang S, Ji L. Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population. J Diabetes Res. 2017;2017:3212814. doi: 10.1155/2017/3212814.

15. De Sanctis V, Gamberini MR, Borgatti L, Atti G, Vullo C, Bagni B. Alpha and beta cell evaluation in patients with thalassaemia intermedia and iron overload. Postgrad Med J. 1985;61(721):963-7. doi: 10.1136/pgmj.61.721.963.

16. Goedecke JH, Dave JA, Faulenbach MV, Utzschneider KM, Lambert EV, West S, Collins M, Olsson T, Walker BR, Seckl JR, Kahn SE, Levitt NS. Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women. Diabetes Care. 2009;32(5):860-5.doi: 10.2337/dc08-2048.

17. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-70. doi: 10.2337/ diacare. 22.9.1462.

18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. doi:10.1007/BF00280883.

19. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32(2):335-41.doi: 10.2337/dc08-1478.

20. Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970-7. doi: 10.1182/blood-2012-02-412692.

21. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, Bellon EM. Magnetic-susceptibility measurement of human iron stores. N Engl J Med.1982;307(27):1671-5. doi: 10.1056/NEJM198212303072703.

22. Pepe A, Meloni A, Rossi G, Midiri M, Missere M, Valeri G, Sorrentino F, D'Ascola DG, Spasiano A, Filosa A, Cuccia L, Dello Iacono N, Forni G, Caruso V, Maggio A, Pitrolo L, Peluso A, De Marchi D, Positano V, Wood JC. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. Eur Heart J Cardiovasc Imaging. 2018;19(3):299-309. doi: 10.1093/ehjci/jex012.

23. Alder R, Roesser EB. Introduction to probability and statistics. WH Freeman and Company Eds. Sixth Edition. San Francisco (USA), 1975.

24. Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. doi: 10.1097/HS9.0000000000000732.

25. Dissanayake R, Samarasinghe N, Waidyanatha S, Pathirana S, Neththikumara N, Dissanayake VHW, Wetthasinghe K, Gooneratne L, Wickramasinghe P. Assessment of iron overload in a cohort of Sri Lankan patients with transfusion dependent beta thalassaemia and its correlation with pathogenic variants in HBB, HFE, SLC40A1, and TFR2 genes. BMC Pediatr. 2022;22(1):344. doi: 10.1186/s12887-022-03191-8.

26. Aimaretti G, Boschetti M, Corneli G, Gasco V, Valle D, Borsotti M, Rossi A, Barreca A, Fazzuoli L, Ferone D, Ghigo E, Minuto F. Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest. 2008;31:445–449. doi: 10.1007/BF03346389.

27. Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Yucel A, Moro Bueno L, Oliva EN. Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review. J Clin Med. 2022 ;11(15):4448. doi: 10.3390/jcm11154448.

28. Aguirre LG, Urrunaga-Pastor D, Moncada-Mapelli E, Guarnizo-Poma M, Lazaro-Alcantara H, Benites-Zapata VA; Insulin Resistance and Metabolic Syndrome Research Group. High serum ferritin levels are associated with insulin resistance but not with impaired glucose tolerance in a healthy people population. Diabetes Metab Syndr. 2017;11 Suppl 2:S983-S988. doi: 10.1016/j.dsx.2017.07.026.

29. Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism. 2011 Mar;60(3):414-420. doi: 10.1016/j.metabol.2010.03.007.

30. Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol. 2011;4(1):17-26. doi: 10.1586/ehm.10.74.

31. Cheesman S, Shah R, Trompeter S, Eleftheriou P, Hylton B, Garbowski MW, Porter J. Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function. Blood. 2018;132 (Supplement 1):1062–1062. doi.org/10.1182/blood-2018-99-119030.

32. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-475. doi: 10.1111/j.1365-2141.2009.07970.x.

33. De Sanctis V, Daar S, Soliman AT, Tzoulis P, Karimi M, Kattamis C. The evolution of glucose-insulin homeostasis in children with β-thalassemia major (β -TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthood. Acta Biomed. 2022 Jul 1;93(3):e2022243. doi: 10.23750/abm.v93i3.12643.

34. De Sanctis V, Soliman A, Tzoulis P, Daar S, Fiscina B, Kattamis C. The Pancreatic changes affecting glucose homeostasis in transfusion dependent β- thalassemia (TDT): a short review. Acta Biomed. 2021;92 (3):e2021232. doi: 10.23750/abm.v92i3.11685.

35. Himoto T, Masaki T. Associations between Zinc Deficiency and Metabolic Abnormalities in Patients with Chronic Liver Disease. Nutrients. 2018;10(1):88.doi: 10.3390/nu10010088.

36. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-23. doi: 10.1152/ajpendo.1979.237.3.E214.

37. Kramer CK, Vuksan V, Choi H, Zinman B, Retnakaran R. Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract. 2014;105(1):88-95. doi: 10.1016/ j. diabres.2014.04.023.

38. Lin YC, Chen HS. Longer time to peak glucose during the oral glucose tolerance test increases cardiovascular risk score and diabetes prevalence. PLoS ONE, 2017: 12(12): e0189047. doi: 10.1371/ journal.pone.0189047.

39. Bervoets L, Mewis A, Massa G. The shape of the plasma glucose curve during an oral glucose tolerance test as an indicator of Beta cell function and insulin sensitivity in end-pubertal obese girls. Horm Metab Res. 2015;47(6):445-51. doi: 10.1055/s-0034-1395551.

40 Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, Kautzky-Willer A. Shape of glucose, insulin, C-peptide curves during a 3-h oral glucose tolerance test: any relationship with the degree of glucose tolerance? Am J Physiol Regul Integr Comp Physiol. 2011;300(4):R941-8. doi: 10.1152/ajpregu.00650.2010.

41. Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, Chetrit A, Abdul-Ghani M, Buysschaert M, Olsen MH, Nilsson PM, Medina JL, Roth J, Groop L, Del Prato S, Raz I, Ceriello A. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). Diabetes Res Clin Pract. 2018;146:18-33. doi: 10.1016/j. diabres. 2018.09.017.

42. De Sanctis V., Soliman A.T., Tzoulis P., Daar S., Di Maio S., Fiscina B., Kattamis C.Glucose metabolism and insulin response to oral glucose tolerance test (OGTT) in prepubertal patients with transfusion-dependent β-thalassemia (TDT): A long-term retrospective analysis.Mediterr J Hematol Infect Dis 2021, 13(1): e2021051

43. Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021;384(8):727-743. doi: 10.1056/NEJMra2021838.

Most read articles by the same author(s)

1 2 3 > >>